Aprocitentan is a Small Molecule owned by Idorsia Pharmaceutical, and is involved in 13 clinical trials, which were completed.

The drug candidate acts as ETA and ETB receptor antagonist. Endothelin interact with ETA receptor leads to the formation of IP3, which causes the release of calcium by the sarcoplasmic reticulum (SR). ETA receptor activation include vasoconstriction, mitogenic activity, electrolyte excretion, microvascular permeability and release of biological mediators. ETA receptor primarily mediates the endothelin-1 in the vasconstriction. Blocking the ETA receptor activation leads to inhibtion of activity of endothelin-1 cause vasodilation.

The revenue for Aprocitentan is expected to reach a total of $2.8bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Aprocitentan NPV Report.

Aprocitentan was originated by Actelion Pharmaceuticals and is currently owned by Idorsia Pharmaceutical. Johnson & Johnson is the other company associated in development or marketing of Aprocitentan.

Aprocitentan Overview

Aprocitentan (ACT-132577) is under development for the treatment of resistant hypertension. It is administered by oral route in the form of tablet. The drug candidate is an active metabolite of macitentan. It is a dual ETA-ETB antagonist. It was also under development for the treatment of mild to moderate essential hypertension. It is a new molecular entity (NME).

Johnson & Johnson Overview

Johnson & Johnson (J&J) researches, develops, manufactures, and sells pharmaceutical products, medical devices, and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; consumer products in oral care, baby care, beauty, over-the-counter (OTC) medicines, women’s health and wound care categories; and medical devices for use in the cardiovascular, orthopaedic, general surgery and vision care fields. J&J distributes pharmaceutical and medical products to retailers, wholesalers, health care professionals and hospitals; and offers consumer products through retail outlets and distributors. The company offers its products in the US; Europe; Asia-Pacific and Africa; and Western Hemisphere (excluding the US). J&J is headquartered in New Brunswick, New Jersey, the US.

The company reported revenues of (US Dollars) US$93,775 million for the fiscal year ended January 2021 (FY2021), an increase of 13.6% over FY2020. In FY2021, the company’s operating margin was 24.3%, compared to an operating margin of 20% in FY2020. In FY2021, the company recorded a net margin of 22.3%, compared to a net margin of 17.8% in FY2020. The company reported revenues of US$23,791 million for the third quarter ended October 2022, a decrease of 1% over the previous quarter.

Quick View – Aprocitentan

Report Segments
  • Innovator
Drug Name
  • Aprocitentan
Administration Pathway
  • Oral
Therapeutic Areas
  • Cardiovascular
Key Companies
Highest Development Stage
  • Pre-Registration

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.